Evolus price target raised to $25 from $22 at Barclays

Barclays analyst Balaji Prasad raised the firm’s price target on Evolus (EOLS) to $25 from $22 and keeps an Overweight rating on the shares. The Evoylsse label includes weight-loss as a cause of facial wrinkles, which is a first and should enhance its GLP-1 related uptake, the analyst tells investors in a research note. The firm says this launch positions Evolus as a stronger competitor and aids in greater account penetration.